Cross-Divisional Guidance for Development of Therapeutics for Severely Debilitating or Life-Threatening (SDLT) Indications

Judith Prescott, DVM, PhD, DACVP (Merck Safety Assessment and Laboratory Animal Resources) on behalf of the SDLT Working Group, IQ DruSafe Preclinical Leadership Group

07Nov2019
Severely-Debilitating or Life-Threatening (SDLT) Indications

• SDLT diseases or conditions are those which cause major irreversible morbidity and/or the likelihood of death is high despite available therapies

• Because of existing guidance that facilitates development of SDLT therapeutics for advanced cancer, today’s presentation is focused on non-oncology SDLT conditions for which there is no adequate therapy

Challenges of Developing Therapeutics for SDLT Indications

- Lack of cross-divisional agreement on development plans for SDLT therapeutics can delay availability of SDLT drugs to patients with high unmet medical needs
  - Results in case-by-case consideration for each program and development delays while seeking regulatory input
    - Existing guidance does not obviate case-by-case requirement
  - SDLT clinical trials may include Ex-US regions/countries, particularly for rare diseases; Delays obtaining agreement from various regions slow availability of potentially beneficial therapies to patients
  - Sponsors default to most conservative approach, obviating ability to accelerate SDLT drug development and availability to patients
Advantages of Cross-Divisional Guidance

• A broadly agreed, cross-divisional guidance would facilitate development of SDLT disease therapeutics with high unmet medical need
  • Enables earlier and continued patient access to potentially beneficial therapies while maintaining standards of safety and efficacy
    • Focus on studies essential to support patient safety in light of unmet medical need
    • Allows rapid advancement to proof-of-concept in patients
    • Expediting an understanding of potential efficacy contributes to benefit versus risk considerations
  • Enables patient and HCP to actively participate in management of patient’s condition including trial participation and continued therapy
Development of SDLT Guidance

- **Existing guidance provides exemplars**
  - ICH S9 Guideline (29Oct2009) and S9 Q&A (12Jun2018) for the Nonclinical Evaluation for Anticancer Pharmaceuticals
  - FDA Guidance for Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals (Mar2019)

- **Defining scope of guidance is an acknowledged challenge, particularly given cross-therapeutic application**
  - Use of defined criteria and list of example indications can provide assurance of appropriate application of guidance to SDLT indications*

- **A cross-divisional SDLT guidance will enable consistency across divisions for a “shared therapeutic context” with significant impact for patients with high unmet medical need**